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Metabolic response to exercise in dialysis patients. The metabolic and
hormonal response to acute moderate intensity (40% of V02 max)
bicycle exercise was examined in eight uremic subjects maintained on
chronic dialysis and in 12 age- and weight-matched controls before and
after the administration of low dose, selective (metoprolol) and non-
selective (propranolol), beta adrenergic antagonists. The fasting plasma
glucose concentration and basal rates of hepatic glucose production
(HGP) and tissue glucose disappearance (Rd) were similar in control
and uremic subjects. In both groups HGP and Rd increased in parallel
during exercise, and the plasma glucose concentration remained con-
stant at the fasting level. However, the increments in Rd (2.27 0.27
vs. 0.87 0.31 mg/kg. mm, P < 0.01) and HGP (2.47 0.22 vs. 0.92
0.19 mg/kg. mm, P < 0.01) were 2.5-3 fold greater in the control
compared to uremic subjects. Although the V02 max was decreased by
50% (39 2vs. 20 2 mllmin kg; P < 0.01), the correlation between
Rd and V02 max was weak (r = 0.33,P < 0.10), suggesting that factors
other than diminished physical fitness contribute to diminished tissue
uptake of glucose in the dialyzed uremic patients. Following the
cessation of exercise, HGP and Rd promptly returned toward basal
levels in both uremic and control subjects. The glucose homeostatic
response to exercise was not significantly altered by either propranolol
or metoprolol. In the postabsorptive state fasting levels of insulin,
glucagon, epinephrine, and norepinephrine all were significantly in-
creased in the uremjc group (P < 0.01 to 0.05). During exercise in the
healthy young controls the plasma insulin concentration declined and
plasma epinephrine and norepinephrine levels rose three- to fourfold. tn
contrast, in uremics plasma insulin failed to fall (P < 0.05) and the
increase in circulating epinephrine and norepinephrine levels was
markedly impaired (P < 0.01). The plasma glucagon concentration did
not change significantly from baseline in either the control or uremic
groups during exercise. Neither low dose propranolol nor metoprolol
altered the hormonal response to exercise in either group.
Patients maintained on chronic hemodialysis are character-
ized by a sedentary lifestyle, a lower degree of physical fitness,
and reduced maximum aerobic capacity [1]. These changes
may, it part, contribute to the accelerated rate of atheroscle-
rosis [2], impaired glucose tolerance [31, and insulin resistance
[4, 5] in uremic patients. In a recent study, Goldberg and
colleagues demonstrated that a chronic physical training pro-
gram is capable of ameliorating many of the endocrine-metabo-
lic abnormalities observed in non-diabetic patients with end-
stage renal failure [6]. However, little is known about the acute
effects of exercise on ghcose metabolism in uremic patients
who are maintained on chronic dialysis.
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During acute exercise in healthy subjects there is an increase
in glucose utilization by the exercising muscle which is pre-
cisely balanced by an equivalent increase in hepatic glucose
production, such that the plasma glucose concentration is
maintained close to the fasting level [7, 8]. This balance
between peripheral glucose uptake and hepatic glucose output
is, in large part, regulated by changes in circulating hormone
levels [7, 81. Thus, increases in glucagon and epinephrine
secretion, in combination with a decline in plasma insulin
concentration, facilitate the increase in hepatic glucose produc-
tion. At present it is unknown whether the metabolic/hormonal
response to exercise is normal in end-stage renal failure patients
who are maintained on dialysis.
Many dialysis patients receive beta adrenergic antagonists for
the treatment of hypertension. Recently, we have demonstrated
that type I diabetic patients demonstrate an altered sensitivity
to the adrenergic regulation of glucose metabolism during acute
exercise [9]. At present, little is known about the adrenergic
regulation of glucose homeostasis during exercise in patients
with end-stage renal failure. This is of interest for several
reasons. First, exercise has been advocated as a means to
improve some of the metabolic disturbances observed in uremic
individuals [6]. And second, uremic patients are commonly
treated with beta adrenergic blocking agents, which may alter
the glucose homeostatic responses to exercise [9].
The present study was undertaken to examine the effect of
acute exercise on glucose metabolism in uremic patients main-
tained on dialysis and to define whether the metabolic/hormonal
responses to exercise are altered by low dose, beta adrenergic
blocking-agents.
Methods
Subject population
Twelve, healthy normal subjects and eight uremic patients
who were maintained on chronic dialysis treatment were stud-
ied. The control group consisted of nine males and three
females (mean age = 27 2 yrs) who were within 15% of their
ideal body weight (mean = 108 3%) based upon medium
frame individuals of the 1959 Metropolitan Life Insurance
Tables. The uremic group consisted of five males and three
females with a mean age of 36 2 yrs who were within 15% of
ideal body weight (mean = 109 4%). The individual clinical
data for the uremic group are summarized in Table 1. No
subject had any evidence of hepatic, cardiovascular, endocrine,
or other major organ system disease other than kidney failure.
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Table 1. Summary ofthe clinical characteristics ofthe 8 uremic patients who participated in the study
Serum urea Plasma Plasma Plasma
Years on Dialysis nitrogen Creatinine potassium bicarbonate phosphate
Patient Sex Diagnosis dialysis treatment mg/dl mg/dl mEq/liter mEqiliter mgldl
TL M Malignant hypertension 8 Hemodialysis 74 20.5 5.0 18 5.0
PL M Glomerulonephritis 10 CAPD 99 18.5 4.9 19 4.9
GD F Glomerulonephritis 1 Hemodialysis 52 18.5 5.1 20 6.4
EL M Unknown 5 CAPD 62 14.5 4.2 25 5.0
ZL F Interstitial nephritis 3 CAPD 55 20.0 4.1 26 4.8
GB F Glomerulonephritis 2 CAPD 47 9.5 3.9 27 4.3
GM M Unknown 3 Hemodialysis 116 18.5 5.0 15 5.0
MJ M Interstitial nephritis 4 Hemodialysis 71 14.5 4.3 16 4.2
Mean SEM 4.5 1.0 72 8 16.8 1.2 4.6 0.2 21 2 4.9 0.2
Except for vitamin supplementation and phosphate binders,
uremic subjects consumed no medications for at least seven
days prior to their participation in the study. There was no
family history of diabetes mellitus in any subject. For at least
three days prior to study all subjects consumed a weight
maintaining diet containing at least 200 grams of carbohydrate
per day. None of the uremic subjects were on a protein
restricted diet. The purpose, nature and potential risks of the
study were explained to each subject before obtaining his/her
voluntary written consent. The experimental protocol was
reviewed and approved by the Human Investigation Committee
of the Yale University School of Medicine.
Experimental protocol
All subjects initially underwent a measurement of their max-
imum aerobic work capacity (V02 max) using a bicycle ergo-
meter. Mean maximal oxygen consumption for the normal
subjects was 39 2 ml/min . kg and for uremics was 20 2
mi/mm kg (P < 0.01). Following determination of the V02
max, each subject participated in three exercise protocols that
were performed in randomized order at seven to ten day
intervals. The exercise was performed on a bicycle ergometer
and the intensity was adjusted to 40% of each subject's V02
max. All studies were begun at 0800 hours following a 10 to 12
hour overnight fast. In the peritoneal dialysis patients all fluid
was drained from the abdomen on the evening prior to study
and the exercise study was carried out on the following morn-
ing. In the hemodialysis patients all studies were carried out 36
to 48 hours after the last dialysis. After the exercise study was
completed, dialysis was begun in both the peritoneal and
hemodialysis groups.
The exercise protocols are described below:
Protocol!. Subjects exercised at 40% of their V02 max for 40
minutes and this was followed by a 30 minute postexercise
recovery period.
Protocol II. For three days prior to exercise subjects ingested
propranolol (Ayerst Laboratories, New York, USA), 40 mg
orally every 12 hours. The last dose of propranolol was taken at
0800 hours on the day of study. Exercise was performed as
described under Protocol I.
Protocol III. For three days prior to exercise subjects in-
gested metoprolol (Ciba Geigy, Summit, New Jersey, USA), 50
mg orally every 12 hours. The last dose of metoprolol was taken
at 0800 hours on the day of study. Exercise was performed as
described under Protocol I.
Neither the subjects nor the investigators knew which drug
(that is, propranoloj or metoprolol) had been consumed until
after the study was completed and the data analyzed.
Two hours prior to the start of exercise a catheter was
inserted into an antecubital vein and subjects received 25 pCi of
3H-3-glucose (New England Nuclear, Boston, Massachusetts,
USA) as an intravenous bolus. This was immediately followed
by a continuous intravenous infusion of tritiated glucose at the
rate of 0.25 pCi/mm. The continuous infusion was maintained
for a two hour period prior to starting exercise, during the 40
minute exercise period, and throughout the 30 minute postexer-
cise recovery period. Plasma samples for the determination of
tritiated glucose specific activity were obtained from a catheter
inserted into the contralateral antecubital vein at five minute
intervals starting 30 minutes prior to exercise and at five minute
intervals throughout the exercise and postexercise recovery
period. Plasma hormone (insulin, giucagon, epinephrine, and
norepinephrine) and free fatty acid (FFA) concentrations were
determined at five to ten minute intervals before, during, and
after exercise.
Calculations
In the basal state the rates of glucose appearance (Ra) and
disappearance (Rd) are equal and were calculated by dividing
the tritiated glucose infusion rate (CPM/min) by the steady
plateau of tritiated glucose specific activity (CPMJnig) which
was achieved during the last 30 minutes of the control period in
all subjects. Following the start of exercise a non-steady state
condition existed for tritiated glucose specific activity and Ra
and Rd were calculated using Steele's equations in their deriv-
ative form [10] with a pool fraction of 0.65 [11]. This technique
has previously been validated for non-steady state conditions
[2, 13]. Data from the peritoneal and hemodialysis patients
were initially analyzed separately. Since no differences between
the two groups were observed, these data were combined for
presentation.
All values in the text and figures represent the mean SEM.
Comparisons between groups were made by analysis of vari-
ance. Changes from baseline within a group were made with the
paired t-test.
Analytical determinations
Plasma glucose concentration was measured using the glu-
cose oxidase method (Glucose Oxidase Analyzer, Beckman
Instruments, Fullerton, California, USA). Plasma insulin con-
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Protocol Basal
Study period
Exercise Recovery
Control
HGP mg/kg mm
Rd mg/kg mm
Plasma glucose mg/dl
2.01 0.10
2.01 0.1081 2
4.48 0.31a
4.28 0.31a
81 2
2.70 0.29
2.75 0.38
79 3
Propranolol
HGP
Rd
Plasma glucose
1.84±0.12
1.84 0.1284 2
4.39±0.15a
3.98 0.23a
79 1
1.79±0.12
1.76 0.21
81 3
Metoprolol
HGP
Rd
Plasma glucose
1.76 0.17
1.76 0.17
83 2
3.74 0.36a
3.60 o.Ioa
83 2
1.51 0.22
1.88 0.2181 2
centration was determined with a double antibody technique
[14]. Plasma glucagon concentration was measured by radioim-
munoassay using the 30K antibody of Unger [15]. Samples for
catecholamines were collected in glutathione and analyzed
using a radioenzymatic assay (Cat-a-Kit, Upjohn Co., Kalama-
zoo, Michigan, USA). Plasma free fatty acid concentrations
(FFA) were determined according to the method of Dole [16] as
modified by Novak [17]. Methods for the determination of
tritiated glucose specific activity have been published previ-
ously [18].
Results
Normal controls
Plasma glucose concentration and glucose turnover. The
fasting plasma glucose concentration, the basal rate of hepatic
glucose production (HGP) and the basal rate of glucose disap-
pearance (Rd) were similar in all three study protocols (Table
2).
During the control study there was a prompt increase in
hepatic glucose production with the onset of exercise, and this
reached a maximum of 4.48 mg/kg . mm at 40 minutes. The
increase in HGP was closely matched by an increase in Rd such
that the plasma glucose concentration remained at the fasting
level (Table 2, Fig. 1). Following the cessation of exercise both
HGP and Rd declined in parallel, reaching values of 2.70 0.29
and 2.75 0.38 mg/kg. mm at 70 minutes, respectively. During
the postexercise recovery period the plasma glucose concentra-
tion did not change significantly from baseline (Table 2, Fig. 1).
When exercise was performed following beta adrenergic
blockade with propranolol, the rises in HGP and Rd were
similar to those observed during the control study. During the
postexercise recovery period both glucose disappearance and
production declined more promptly to baseline compared to the
control study (Table 2, Fig. 1). Changes in HGP and Rd
following metoprolol were quite similar to those observed with
propranolol (Table 2, Fig. 1).
Plasma hormone and FFA concentrations. In the control
study the fasting plasma insulin concentration declined from 14
to 11 U/ml (P < 0.05) during exercise and then increased to
levels slightly above basal during the postexercise recovery
period. The decrease in plasma insulin concentration when
exercise was performed with both propranolol and metoprolol
was more pronounced than during the control study (Table 3).
Plasma glucagon tended to rise during both the exercise and
postexercise recovery periods during all three study protocols,
but in none did the increase reach statistical significance (Table
3).
Both epinephrine and norepinephrine rose five- to sixfold
during exercise in the control study and returned toward
baseline during the postexercise recovery period. A similar
pattern was observed during both the propranolol and meto-
prolol studies.
Basal plasma FFA concentrations, 731 68 mol/liter,
increased during exercise in the control study and remained
elevated during the postexercise recovery period (Table 3).
Following both propranolol (495 46 moUliter) and meto-
prolol (530 57 smol/liter) the fasting plasma FFA concentra-
tions were significantly reduced (P < 0.01). In contrast to the
increase in plasma FFA observed in the control study, follow-
ing both propranolol and metoprolol exercise was associated
with a decline in the plasma FFA concentration (Table 3).
During the postexercise recovery period the plasma FFA
Table 2. Effect of beta adrenergic blockade on glucose turnover
during exercise in normal subjects
4
E
E
2
Plasma glucose concentration, HGP, and Rd are shown during the
basal state, at the end of the 40 mm exercise period, and at the end of
the 30 mm postexercise recovery period. All results are expressed as
the mean SEM.
a P < 0.01 vs. baseline
4
2
Time, mm
Fig. 1. Time related change in the rate of glucose appearance (Ra), and
the rate of glucose disappearance (Rd) in healthy young subjects during
exercise (0 to 40 mm) and during the postexercise recovery period (40 to
70 mm) in the control (solid circles), propranolol (open squares), and
metoprolol (open triangles) studies. Ra is equivalent to the rate of
hepatic glucose production (HPG). All values represent the mean
SEM.
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Protocol Basal
Study period
Exercise Recovery
Control
Insulin xU/mi
Glucagon pg/mI
Epi pg/mI
NE pg/mI
FFA Mmol/ljter
14 2
86 11
26 3
215 15
731 68
11 2
95 12
166 36b
1269 115
988 th l42
16 2
100 12
40 6
300 32
1019 ll8
Propranolol
Insulin
Glucagon
Epi
NE
FFA
16 2
111 1827 4
219 25
495 46"
10 ia
133 23
188 15$'
1058 124b
381 45"
16 I
147 2753 5
273 29"
536 64"
Metoprolol
Insulin
Glucagon
Epi
NE
FFA
18 2
125 30
30 4
223 14
530 57"
11 2
118 27
157 16b
1224 142b
436 62"
17 2
127 20
48 6
289 26"
594 87"
Plasma insulin, glucagon, epinephrine (Epi), norepinephrine (NE),
and free fatty acid (FFA) concentrations are shown during the basal
state, at the end of the 40 mm period of exercise and at the end of the 30
mm postexercise recovery period. All results are expressed as the mean
SEM.
a P < 0.05 vs. basal
bp<001 vs. basal
"P < 0.01 vs. the control study
Table 4. Effect of beta adrenergic blockade on glucose turnover
during exercise in uremic subjects
Protocol Basal
Study period
Exercise Recovery
Control
HGP mg/kg mm
Rd mg/kg ' mm
Plasma glucose mg/dl
1.88 0.10
1.88 0.10
77 2
2.80 0,35b,c
2.75 018b,c
81 2
1.94 0.26
1.72 0.10
75 2
Propranolol
HGP
Rd
Plasma glucose
2.06 0.20
2.06 0.20
82 2
2.79 0.23a,c
2.88 o.lsac
80 4
2.33 0.20
2,20 0.31
74 3
Metoprolol
HOP
Rd
Plasma glucose
1.98 0.10
1.98 0.10
82 2
3.23 21"
3.12 0•23b
82 3
1.85 0.15
2.11 0.23
79 3
Plasma glucose concentration, HOP, and Rd are shown during the
basal state, at the end of the 40 mm exercise period, and at the end of
the 30 mm postexercise recovery period. All results are expressed as
the mean SEM.
a P < 0.05 and b P < 0.01 vs. baseline; "P< 0.05 vs. healthy control
subjects
increased to or above the basal level in the propranolol and
metoprolol studies.
Uremic patients
Plasma glucose concentration and glucose turnover. In the
basal state the fasting plasma glucose concentration, hepatic
glucose production (HGP), and the rate of glucose disappear-
Exercise r Recovery4N
I I I
Time, mm
Fig. 2. Time related change in the rate of glucose appearance (Ru), and
the rate of glucose disappearance (Rd) in uremic subjects during
exercise (0 to 40 mm) and during the post exercise recovery period (40 to
70 mm) in the control (solid circles), propranolol (open squares), and
metoprolol (open triangles) studies. Ra is equivalent to the rate of
hepatic glucose production. All values represent the mean SEM.
ance (Rd) were similar in all three study protocols (Table 4, Fig.
2).
During the control study the fasting plasma glucose concen-
tration in the uremic subjects increased slightly during exercise
and then returned to the basal level during the postexercise
recovery period. The plasma glucose concentration did not
change significantly from baseline during exercise in either the
propranolol or metoprolol studies (Table 4, Fig. 2). The basal
rates of hepatic glucose production and tissue glucose disap-
pearance in uremic subjects (Table 4) were similar to those
observed in the healthy controls (Table 2) during all three study
protocols. During exercise the increase in Rd was closely
paralleled by the increase in HGP in the control, propranolol,
and metoprolol protocols (Table 4, Fig. 2). However, the
increment in both Rd and HGP were reduced by 50 to 60% in
the uremic compared to healthy control subjects (P < 0.01).
Even if the increment in Rd (Rd max—Rd basal) is factored by
the increment in oxygen consumption (VO2max—VO2basal), a
significant reduction is observed in the uremic group (0.048
0.009 vs. 0.067 0.008 mg/kg. mm, P <0.05).
Within the uremic group no differences in Rd or HGP were
observed between patients maintained on hemo- versus perito-
neal dialysis.
Plasma hormone and FFA concentrations. The fasting plasma
insulin concentration in the uremic patients was slightly, al-
though not significantly greater than in the controls in all three
study protocols. In contrast to the controls, the plasma insulin
concentration failed to decrease from basal levels during exer-
cise in either of the three studies. The fasting plasma glucagon
concentration was elevated approximately fivefold in the ure-
Table 3. Effect of beta adrenergic blockade on the hormonal
response to exercise in normal subjects 4
. 3
E
E
0 10 20 30 40 50 60 70
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Table 5. Effect ofbeta adrenergic blockade on the hormonal
response to exercise in uremic subjects
Protocol Basal
Study period
Exercise Recovery
Control
Insulin rxU/mi
Glucagon pg/mi
16 2
550 8O'
16 2
486 40
16 2
561 80
Epi pg/mi
NE pg/mi
FFA pinoi/l
94 19d
823 200'
554 110
147 3l
1498 210b
713 102b
93 23
775 157
811 190k
Propranolol
Insulin 20 4 20 4 20 4
Glucagon
Epi
NE
477 35d
80 26d
868 153d
460 15
195 54
1423 224b
472 33
109 26
947 170
FFA 449 110 356 60C 606 136
Metoprolol
Insulin 20 4 19 4 20 4
Glucagon 489 73d 459 42 476 57
Epi 93 33d 220 40 103 38
NE 907 239d 1791 319b 972 161
FFA 404 60 359 52C 443 126C
Plasma insulin, glucagon, epinephrine (Epi), norepinephrine (NE),
and free fatty acid (FFA) concentrations are shown during the basal
state, at the end of the 40 mm exercise period, and at the end of the 30
mm postexercise recovery period. All results are expressed as the mean
SEM. a P < 0.05 and b p < 0.01 vs. basal; P < 0.05 vs. the control
study; d P < 0.05 vs. healthy young subjects
mic compared to healthy control subjects and, as was observed
in the controls, failed to increase following exercise (Table 5).
Baseline epinephrine and norepinephrine concentrations were
increased three- to four-fold in the uremic group (P < 0.01).
During exercise both the incremental response, as well as the
percent increment above baseline, were significantly dimin-
ished in the uremic compared to control subjects (P < 0.01),
even though the absolute plasma catecholamine concentrations
achieved were similar in two groups (Tables 2, 5). During the
postexercise recovery period plasma epinephrine and norepi-
nephrine concentrations returned to basal levels in all three
study protocols.
The fasting plasma FFA concentration was moderately,
although not significantly reduced in the uremic group (Table 5).
Following exercise and during the postexercise recovery period
the incremental plasma FFA response was similar to that
observed in the healthy control group. Following both propran-
olol and metoprolol the fasting plasma FFA concentration
decreased slightly and the normal increase in circulating FFA
levels in response to exercise was not observed; in contrast, a
significant decline in plasma FFA occurred in response to
exercise. During the postexercise recovery period the plasma
FFA concentration increased to or above basal levels in the
propranolol and metoprolol studies.
Discussion
Decreased physical fitness has been associated with an ac-
celerated rate of atherosclerosis [19], impaired glucose toler-
ance [20, 21], insulin resistance [22, 231, hyperinsulinemia [19,
20], and hyperlipidemia [24]. Similar metabolic disturbances
and cardiovascular risk factors have been reported in uremic
Table 6. Effect of beta adrenergic blockade on mean arterial blood
pressure and heart rate during exercise in control and uremic subjects
Protocol Basal
Study period
Exercise Recovery
Normals
Control
Heart rate 62 4 142 3d 73 5C
Mean BP 91 3 95 2 89 3
Metoprolol
Heart rate 50 2a 108 5b,d 64
Mean BP 86 3 91 5 87 3
Propanolol
Heart rate 54 3a 111 4b,d 61 4
MeanBP 84±4a 90±4 88±4
Uremics
Control
Heart rate 73 3 125 4d 86 3C
MeanBP 96±3 102±3 98±3
Metoprolol
Heart rate 62 3 91 5'" 68 3*C
Mean BP 83 6 87 3b 82 4b
Propranolol
Heart rate 65 3 98 3b,d 74 3b,c
Mean BP 88 a 94 4 85 5
Mean arterial blood pressure (mm Hg) and heart rate (beats/minute)
are shown during the basal state, at the end of the 40 mm exercise
period, and at the end of the 30 mm post exercise recovery period in
control and uremic subjects. All results are expressed as the mean
SEM. a p < 0.05 vs. control, b P<0.01 vs. control, C P <0.05 vs. basal,d P < 0.01 vs. basal
individuals [1—SI. Recently, Goldberg and colleagues demon-
strated that a chronic exercise program can reverse many of the
metabolic disturbances that have been demonstrated in uremic
patients [6] and they have suggested that exercise be employed
to improve the cardiovascular risk profile in such individuals
[25]. However, little information is presently available concern-
ing the metabolic compensations to a bout of acute physical
exercise in patients with end-stage renal failure. In the present
study we have examined the glucose and hormonal responses to
moderate intensity exercise in uremic patients maintained on
chronic dialysis. The intensity of exercise was set at 40% of
V02 max because this is within the capacity of an average
untrained individual without causing profound exhaustion. Be-
cause many uremic patients are treated with beta adrenergic
blocking agents and these agents have been shown to alter the
metabolic response to exercise in patients with impaired glu-
cose tolerance such as diabetes mellitus [9], we also examined
the effect of low dose, non-specific (propranolol) and specific
(metoprolol), beta blocking agents on the glucose/hormonal
responses to exercise.
In healthy young subjects exercise was associated with a five
to sixfold rise in circulating epinephrine and norepinephrine
levels and a decline in the plasma insulin concentration. Similar
changes have been reported by others [7, 8, 26, 27]. The decline
in plasma insulin has been shown to be mediated via alpha
adrenergic stimulation which inhibits insulin secretion by the
pancreas [28, 29]. The increase in plasma catecholamine con-
centration, in combination with the decrease in plasma insulin,
are believed to facilitate the rise in hepatic glucose production
to meet the demands of the exercising muscle [7, 8, 26, 27, 30].
No change in circulating plasma glucagon levels was observed.
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This is consistent with previously published reports in which
moderate intensity exercise has been employed [9, 311. When
exercise was performed with the chronic administration of beta
adrenergic antagonists (both propranolol and metoprolol), the
increases in Rd and HGP were similar to the control study,
indicating that beta stimulation is not an absolute requirement
in order to observe a normal glucose homeostatic response to
exercise. We [9], as well as others [32], have reported similar
results when exercise was performed after acute adrenergic
blockade with propranolol. In contrast, in insulin-dependent
diabetic subjects propranolol markedly inhibited the exercise
induced rise in HGP and augmented peripheral glucose dis-
posal, leading to significant hypoglycemia [9].
In uremic subjects maintained on chronic dialysis the maxi-
mum aerobic capacity was decreased by 50%, documenting a
markedly reduced level of physical fitness. Similar observations
have been made by others [1]. Nonetheless, when exercise was
performed at the same relative intensity (40% of V02 max) as in
healthy young control subjects, tissue glucose disposal (Rd)
increased and this was precisely matched by a rise in HGP,
such that the plasma glucose concentration did not change
significantly from baseline. It is noteworthy, however, that the
absolute, as well as the incremental rises in both Rd and HGP
were reduced by approximately 60 — 65% (P < 0.01) in the
uremic compared to control group.
It is particularly noteworthy that the V02 max in the uremic
subjects was reduced by 40 to 50% compared to controls (P <
0.01). Since all subjects exercised at a constant percentage
(40%) of their V02 max, the absolute work intensity must have
been reduced by 40 to 50% in the uremic group. Since the
absolute work intensity is an important determinant of amount
of glucose utilized by the exercising muscle [7], it is not
surprising that tissue glucose uptake (Rd) was significantly
lower in the uremic patients. However, the increment in Rd in
the uremic compared to control group (0.87 vs. 2.27 mg/kg. mm)
was lower than what could be expected on the basis of the
reduction in V02 max. Thus, if one calculates the increment in
Rd per increment in oxygen consumption, a significant reduc-
tion (0.048 vs. 0.067; P < 0.05) is observed. Furthermore, the
V02 max was poorly correlated with the Rd (r = 0.32, P <
0.10). These results suggest that factors other than the degree of
physical fitness may be responsible for the diminished increase
in tissue glucose disposal during exercise in the uremic group.
Since plasma FFA levels tended to be lower in uremic com-
pared to control subjects, this substrate can not account for the
diminished increase in Rd. It is well documented that peripheral
tissues, primarily muscle, of uremic patients are markedly
resistant to the action of insulin [3—5]. It is possible that this
resistance also extends to the ability of exercise to promote
muscle glucose uptake.
The possibility should also be considered that the decrease in
peripheral glucose uptake is, in part, related to decreased
substrate availability due to an impairment in hepatic glucose
output. With regard to this possibility, basal plasma insulin
levels tended to be increased in uremic patients and failed to
decline during exercise. This would tend to inhibit hepatic
glucose output. Similarly, although fasting plasma catechola-
mine levels were increased in uremic individuals, the increases
in both plasma epinephrine and norepinephrine (Table 5) during
exercise were markedly diminished compared to control sub-
jects (Table 3). It is possible that the diminished incremental
plasma catecholamine response in uremic subjects, in combi-
nation with the lack of decline in plasma insulin concentration,
may in part be responsible for the failure of HGP to increase to
the same level as observed in the controls.
It is important to emphasize that neither propranolol, a
non-specific beta 1-beta 2 antagonist, nor metoprolol, a specific
beta 1 antagonist, altered the exercise-related increase in Rd or
HGP in uremic subjects. This has important clinical implica-
tions, since it indicates that exercise can safely be performed in
uremic subjects who are being treated with beta blocking agents
without the risk of developing hypoglycemia. This is in contrast
to diabetic subjects who manifest an altered adrenergic sensi-
tivity to beta adrenergic antagonists and are predisposed to the
development of clinically significant hypoglycemia [9].
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